NEGGRAM Drug Patent Profile
✉ Email this page to a colleague
When do Neggram patents expire, and what generic alternatives are available?
Neggram is a drug marketed by Sanofi Aventis Us and is included in two NDAs.
The generic ingredient in NEGGRAM is nalidixic acid. There are two drug master file entries for this compound. Additional details are available on the nalidixic acid profile page.
Summary for NEGGRAM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 133 |
Patent Applications: | 4,226 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NEGGRAM at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for NEGGRAM
US Patents and Regulatory Information for NEGGRAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | NEGGRAM | nalidixic acid | SUSPENSION;ORAL | 017430-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NEGGRAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-004 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-005 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
Sanofi Aventis Us | NEGGRAM | nalidixic acid | SUSPENSION;ORAL | 017430-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-002 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
Sanofi Aventis Us | NEGGRAM | nalidixic acid | SUSPENSION;ORAL | 017430-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NEGGRAM
See the table below for patents covering NEGGRAM around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 103236 | ⤷ Try a Trial | |
Austria | 252248 | ⤷ Try a Trial | |
Belgium | 767505 | ⤷ Try a Trial | |
Sweden | 306743 | ⤷ Try a Trial | |
Netherlands | 6705465 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |